Oncogenes and tumor suppressor genes: Comparative genomics and network perspectives

Kevin Zhu, Qi Liu, Yubo Zhou, Cui Tao, Zhongming Zhao, Jingchun Sun, Hua Xu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Defective tumor suppressor genes (TSGs) and hyperactive oncogenes (OCGs) heavily contribute to cell proliferation and apoptosis during cancer development through genetic variations such as somatic mutations and deletions. Moreover, they usually do not perform their cellular functions individually but rather execute jointly. Therefore, a comprehensive comparison of their mutation patterns and network properties may provide a deeper understanding of their roles in the cancer development and provide some clues for identification of novel targets. Results: In this study, we performed a comprehensive survey of TSGs and OCGs from the perspectives of somatic mutations and network properties. For comparative purposes, we choose five gene sets: TSGs, OCGs, cancer drug target genes, essential genes, and other genes. Based on the data from Pan-Cancer project, we found that TSGs had the highest mutation frequency in most tumor types and the OCGs second. The essential genes had the lowest mutation frequency in all tumor types. For the network properties in the human protein-protein interaction (PPI) network, we found that, relative to target proteins, essential proteins, and other proteins, the TSG proteins and OCG proteins both tended to have higher degrees, higher betweenness, lower clustering coefficients, and shorter shortest-path distances. Moreover, the TSG proteins and OCG proteins tended to have direct interactions with cancer drug target proteins. To further explore their relationship, we generated a TSG-OCG network and found that TSGs and OCGs connected strongly with each other. The integration of the mutation frequency with the TSG-OCG network offered a network view of TSGs, OCGs, and their interactions, which may provide new insights into how the TSGs and OCGs jointly contribute to the cancer development. Conclusions: Our study first discovered that the OCGs and TSGs had different mutation patterns, but had similar and stronger protein-protein characteristics relative to the essential proteins or control proteins in the whole human interactome. We also found that the TSGs and OCGs had the most direct interactions with cancer drug targets. The results will be helpful for cancer drug target identification, and ultimately, understanding the etiology of cancer and treatment at the network level.

Original languageEnglish (US)
Article numberS8
JournalBMC Genomics
Volume16
Issue number7
DOIs
StatePublished - Jun 11 2015
Externally publishedYes

Fingerprint

Genomics
Tumor Suppressor Genes
Oncogenes
Neoplasms
Proteins
Mutation Rate
Tumor Suppressor Proteins
Gene Regulatory Networks
Oncogene Proteins
Essential Genes
Pharmaceutical Preparations
Mutation
Genes
Protein Interaction Maps
Sequence Deletion
Cluster Analysis
Cell Proliferation
Apoptosis

ASJC Scopus subject areas

  • Biotechnology
  • Genetics

Cite this

Oncogenes and tumor suppressor genes : Comparative genomics and network perspectives. / Zhu, Kevin; Liu, Qi; Zhou, Yubo; Tao, Cui; Zhao, Zhongming; Sun, Jingchun; Xu, Hua.

In: BMC Genomics, Vol. 16, No. 7, S8, 11.06.2015.

Research output: Contribution to journalArticle

Zhu, Kevin ; Liu, Qi ; Zhou, Yubo ; Tao, Cui ; Zhao, Zhongming ; Sun, Jingchun ; Xu, Hua. / Oncogenes and tumor suppressor genes : Comparative genomics and network perspectives. In: BMC Genomics. 2015 ; Vol. 16, No. 7.
@article{a27cb24a7438489ca547cd72fe993373,
title = "Oncogenes and tumor suppressor genes: Comparative genomics and network perspectives",
abstract = "Background: Defective tumor suppressor genes (TSGs) and hyperactive oncogenes (OCGs) heavily contribute to cell proliferation and apoptosis during cancer development through genetic variations such as somatic mutations and deletions. Moreover, they usually do not perform their cellular functions individually but rather execute jointly. Therefore, a comprehensive comparison of their mutation patterns and network properties may provide a deeper understanding of their roles in the cancer development and provide some clues for identification of novel targets. Results: In this study, we performed a comprehensive survey of TSGs and OCGs from the perspectives of somatic mutations and network properties. For comparative purposes, we choose five gene sets: TSGs, OCGs, cancer drug target genes, essential genes, and other genes. Based on the data from Pan-Cancer project, we found that TSGs had the highest mutation frequency in most tumor types and the OCGs second. The essential genes had the lowest mutation frequency in all tumor types. For the network properties in the human protein-protein interaction (PPI) network, we found that, relative to target proteins, essential proteins, and other proteins, the TSG proteins and OCG proteins both tended to have higher degrees, higher betweenness, lower clustering coefficients, and shorter shortest-path distances. Moreover, the TSG proteins and OCG proteins tended to have direct interactions with cancer drug target proteins. To further explore their relationship, we generated a TSG-OCG network and found that TSGs and OCGs connected strongly with each other. The integration of the mutation frequency with the TSG-OCG network offered a network view of TSGs, OCGs, and their interactions, which may provide new insights into how the TSGs and OCGs jointly contribute to the cancer development. Conclusions: Our study first discovered that the OCGs and TSGs had different mutation patterns, but had similar and stronger protein-protein characteristics relative to the essential proteins or control proteins in the whole human interactome. We also found that the TSGs and OCGs had the most direct interactions with cancer drug targets. The results will be helpful for cancer drug target identification, and ultimately, understanding the etiology of cancer and treatment at the network level.",
author = "Kevin Zhu and Qi Liu and Yubo Zhou and Cui Tao and Zhongming Zhao and Jingchun Sun and Hua Xu",
year = "2015",
month = "6",
day = "11",
doi = "10.1186/1471-2164-16-S7-S8",
language = "English (US)",
volume = "16",
journal = "BMC Genomics",
issn = "1471-2164",
publisher = "BioMed Central",
number = "7",

}

TY - JOUR

T1 - Oncogenes and tumor suppressor genes

T2 - Comparative genomics and network perspectives

AU - Zhu, Kevin

AU - Liu, Qi

AU - Zhou, Yubo

AU - Tao, Cui

AU - Zhao, Zhongming

AU - Sun, Jingchun

AU - Xu, Hua

PY - 2015/6/11

Y1 - 2015/6/11

N2 - Background: Defective tumor suppressor genes (TSGs) and hyperactive oncogenes (OCGs) heavily contribute to cell proliferation and apoptosis during cancer development through genetic variations such as somatic mutations and deletions. Moreover, they usually do not perform their cellular functions individually but rather execute jointly. Therefore, a comprehensive comparison of their mutation patterns and network properties may provide a deeper understanding of their roles in the cancer development and provide some clues for identification of novel targets. Results: In this study, we performed a comprehensive survey of TSGs and OCGs from the perspectives of somatic mutations and network properties. For comparative purposes, we choose five gene sets: TSGs, OCGs, cancer drug target genes, essential genes, and other genes. Based on the data from Pan-Cancer project, we found that TSGs had the highest mutation frequency in most tumor types and the OCGs second. The essential genes had the lowest mutation frequency in all tumor types. For the network properties in the human protein-protein interaction (PPI) network, we found that, relative to target proteins, essential proteins, and other proteins, the TSG proteins and OCG proteins both tended to have higher degrees, higher betweenness, lower clustering coefficients, and shorter shortest-path distances. Moreover, the TSG proteins and OCG proteins tended to have direct interactions with cancer drug target proteins. To further explore their relationship, we generated a TSG-OCG network and found that TSGs and OCGs connected strongly with each other. The integration of the mutation frequency with the TSG-OCG network offered a network view of TSGs, OCGs, and their interactions, which may provide new insights into how the TSGs and OCGs jointly contribute to the cancer development. Conclusions: Our study first discovered that the OCGs and TSGs had different mutation patterns, but had similar and stronger protein-protein characteristics relative to the essential proteins or control proteins in the whole human interactome. We also found that the TSGs and OCGs had the most direct interactions with cancer drug targets. The results will be helpful for cancer drug target identification, and ultimately, understanding the etiology of cancer and treatment at the network level.

AB - Background: Defective tumor suppressor genes (TSGs) and hyperactive oncogenes (OCGs) heavily contribute to cell proliferation and apoptosis during cancer development through genetic variations such as somatic mutations and deletions. Moreover, they usually do not perform their cellular functions individually but rather execute jointly. Therefore, a comprehensive comparison of their mutation patterns and network properties may provide a deeper understanding of their roles in the cancer development and provide some clues for identification of novel targets. Results: In this study, we performed a comprehensive survey of TSGs and OCGs from the perspectives of somatic mutations and network properties. For comparative purposes, we choose five gene sets: TSGs, OCGs, cancer drug target genes, essential genes, and other genes. Based on the data from Pan-Cancer project, we found that TSGs had the highest mutation frequency in most tumor types and the OCGs second. The essential genes had the lowest mutation frequency in all tumor types. For the network properties in the human protein-protein interaction (PPI) network, we found that, relative to target proteins, essential proteins, and other proteins, the TSG proteins and OCG proteins both tended to have higher degrees, higher betweenness, lower clustering coefficients, and shorter shortest-path distances. Moreover, the TSG proteins and OCG proteins tended to have direct interactions with cancer drug target proteins. To further explore their relationship, we generated a TSG-OCG network and found that TSGs and OCGs connected strongly with each other. The integration of the mutation frequency with the TSG-OCG network offered a network view of TSGs, OCGs, and their interactions, which may provide new insights into how the TSGs and OCGs jointly contribute to the cancer development. Conclusions: Our study first discovered that the OCGs and TSGs had different mutation patterns, but had similar and stronger protein-protein characteristics relative to the essential proteins or control proteins in the whole human interactome. We also found that the TSGs and OCGs had the most direct interactions with cancer drug targets. The results will be helpful for cancer drug target identification, and ultimately, understanding the etiology of cancer and treatment at the network level.

UR - http://www.scopus.com/inward/record.url?scp=84969220125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969220125&partnerID=8YFLogxK

U2 - 10.1186/1471-2164-16-S7-S8

DO - 10.1186/1471-2164-16-S7-S8

M3 - Article

AN - SCOPUS:84969220125

VL - 16

JO - BMC Genomics

JF - BMC Genomics

SN - 1471-2164

IS - 7

M1 - S8

ER -